Abstract Body

Background

Post-treatment controllers (PTCs) are people with HIV (PWH) who achieved low/no viremia during analytical treatment interruption (ATI). Multiple mechanisms could potentially account for post-treatment control. In this study, we leveraged ACTG ATI studies to evaluate proteomic signatures of PTCs and non-controllers (NCs) before and during ATI.

Methods

We used Olink Inflammatory I and Flex panels to measure 381 proteins in cryopreserved plasma. Protein levels were compared between PTCs and NCs at pre-ATI, early ATI (before or at early phase of viral rebound), and late ATI. Multivariate linear models were constructed using protein levels as dependent variables and PTC status, age, sex, acute HIV as independent variables. Proteomic changes within groups between different time points were compared using paired T-test. False detection rate (FDR) was calculated with the Benjamini-Hochberg method. We used Gene Set Enrichment Analysis (GSEA) to evaluate differential pathways. 

Results

We included 15 PTCs and 25 NCs, with comparable demographics. 38% started ART during acute HIV. Before ATI, all were virally suppressed and no significant differentially expressed proteins (DEPs) were detected accounting for FDR. However, PTCs showed enriched tumor necrosis factor-alpha (TNF-α) signaling in Hallmark gene sets pre-ATI (normalized enrichment score [NES] 1.80, P=0.002, FDR=0.08). Using Elastic Net feature selection, we identified 73 proteins that collectively distinguished PTCs from NCs (Fig. 1A), with most important ones including PTX3 (enriched in PTCs) and DNPH1, PSMG3 (enriched in NCs). The early post-ATI time point was within 4 weeks of ATI, at or preceding the time of viral rebound. Compared to NCs, PTCs at early ATI showed higher levels of interferon (IFN)-β response (Gene Ontology, NES= 1.75, P=0.00013, FDR=0.09) and mounted coordinated T cell activation and type II interferon production responses associated with maintaining viral control. In contrast, at the late ATI time point (median, 31 weeks for PTC and 4 weeks for NCs), NCs demonstrated significantly elevated immune activation and inflammation (Fig. 1B).

Conclusions

PTCs had unique proteomic signatures before and during ATI. Compared to NCs, PTCs demonstrated early activation in TNF-α pathways pre-ATI and a timely, coordinated response early in the ATI while maintaining viral control. These results provide insights into the mechanisms behind post-treatment control and potential targets for future HIV remission trials.

Table or Figure